Skip to main content
SpringerLink
Log in
Book cover

Regional Chemotherapy pp 249–261Cite as

Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy for Gastric Cancer

  • Chapter

  • 100 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Worldwide, gastric cancer (GC) remains a major cause of cancer mortality. Although its incidence has declined over the last few decades, it remains a major public health problem, now ranking eighth globally in terms of annual cancer-related deaths. In addition, the number of patients with newly diagnosed proximal gastric and gastroesophageal junction adenocarcinomas continues to rise (1–3).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cameron AJ, Ott BJ, and Payne WS. Incidence of adenocarcinoma in columnar-lined (Barrett’s) esophagus, N. Engl. J. Med., 313 (1985) 857–859.

    Article  PubMed  CAS  Google Scholar 

  2. Hesketh PJ, Clapp RW, Doos WG, and Spechler SJ. Increasing frequency of adenocarcinoma of the esophagus, Cancer, 64 (1989) 526–530.

    Article  PubMed  CAS  Google Scholar 

  3. Blot WJ, Devesa SS, Kneller RW, and Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia, JAMA, 265 (1991) 1287–1289.

    Article  PubMed  CAS  Google Scholar 

  4. Landis SH, Murray T, Bolden S, and Wingo PA. Cancer statistics, CA. Cancer J. Clin., 48 (1998) 6–29.

    Article  PubMed  CAS  Google Scholar 

  5. Noguchi Y, Imada T, Matsumoto A, Coit DG, and Brennan MF. Radical surgery for gastric cancer. A review of the Japanese experience, Cancer, 64 (1989) 2053–2062.

    Google Scholar 

  6. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr., Winchester D, and Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons, Ann. Surg., 218 (1993) 583–592.

    Article  PubMed  CAS  Google Scholar 

  7. Botet JF, Lightdale CJ, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT, Radiology, 181 (1991) 426–432.

    PubMed  CAS  Google Scholar 

  8. Wisbeck WM, Becher EM, and Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist, Radiother. Oncol., 7 (1986) 13–18.

    Article  PubMed  CAS  Google Scholar 

  9. McNeer G, Vanderberg H, and Donn F. Critical evaluation of subtotal gastrectomy for the cure of the stomach, Ann. Surg., 134 (1951) 1–7.

    Article  Google Scholar 

  10. Gunderson LL and Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy, Int. J. Radiat. Oncol. Biol. Phys., 8 (1982) 1–11.

    Article  PubMed  CAS  Google Scholar 

  11. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, and Sullinger J. Patterns of failure following curative resection of gastric carcinoma, Int. J. Radiat. Oncol. Biol. Phys., 19 (1990) 1357–1362.

    Article  PubMed  CAS  Google Scholar 

  12. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery, Cancer, 79 (1997) 884–891.

    Article  PubMed  CAS  Google Scholar 

  13. Yashiro M, Chung YS, Nishimura S, Inoue T, and Sowa M. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice, Clin. Exp. Metastasis, 14 (1996) 43–54.

    Article  PubMed  CAS  Google Scholar 

  14. Nakajima T. Review of adjuvant chemotherapy for gastric cancer, World J. Surg., 19 (1995) 570–574.

    Article  PubMed  CAS  Google Scholar 

  15. Heymans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials, J. Clin. Oncol., 11 (1993) 1441–1447.

    Google Scholar 

  16. Ajani JA, Ota DM, and Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma, Cancer, 67 (Suppl 1) (1991) 260–265.

    Article  PubMed  CAS  Google Scholar 

  17. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma, J. Natl. Cancer Inst., 85 (1993) 1839–1844.

    Article  PubMed  CAS  Google Scholar 

  18. Rougier P, Mahjoubi M, Lasser P, et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma: a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum, Eur. J. Cancer, 9 (1994) 1269–1275.

    Article  Google Scholar 

  19. Archer S and Gray B. Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases, Surgery, 108 (1990) 502–507.

    PubMed  CAS  Google Scholar 

  20. Markman M. Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract, Surg. Gynecol. Obstet., 164 (1987) 89–93.

    PubMed  CAS  Google Scholar 

  21. Kelsen DP, Saltz L, Cohen AM, et al. Phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer, Cancer, 74 (1994) 2224–2233.

    Article  PubMed  CAS  Google Scholar 

  22. Sugarbaker PH. Early postoperative intraperitoneal adriamycin as an adjuvant treatment for advanced gastric cancer with lymph node or serosal invasion, Cancer Treat. Res., 55 (1991) 277–284.

    Article  PubMed  CAS  Google Scholar 

  23. Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy, Cancer Treat. Res., 81 (1996) 149–168.

    Article  PubMed  CAS  Google Scholar 

  24. Sugarbaker PH. Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy, J. Surg. Oncol., 2 (Suppl), (1991) 36–41.

    Article  CAS  Google Scholar 

  25. Atiq OT, Kelsen DP, Shiu MH, et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer, J. Clin. Oncol., 11 (1993) 425–433.

    PubMed  CAS  Google Scholar 

  26. Hamazoe R, Maeta M, and Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study, Cancer, 73 (1994) 2048–2052.

    Article  PubMed  CAS  Google Scholar 

  27. Hagiwara A, Takahashi T, Sawai K, Yamaguchi T, Iwamoto A, and Yoneyama C. Intraoperative chemotherapy against peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles adsorbing mitomycin C, Gan. To Kagaku Ryoho., 16 (1989) 187–192.

    PubMed  CAS  Google Scholar 

  28. Schiessel R, Funovics J, Schick B, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial, Acta. Med. Austriaca., 16 (1989) 68–69.

    PubMed  CAS  Google Scholar 

  29. Sautner T, Hofbauer F, Depisch D, Schiessel R, and Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer, J. Clin. Oncol., 12 (1994) 970–974.

    PubMed  CAS  Google Scholar 

  30. Rosen H, Jatzko G, Repse R, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology, J. Clin. Oncol., 16 (1998) 2733–2738.

    PubMed  CAS  Google Scholar 

  31. Inoue Y, Yamashiro H, Sawada T, et al. Therapeutic results and pharmacokinetics of combined used anticancer drug in intraperitoneal hyperthermo-chemotherapy (CHPP), Gan. To Kagaku Ryoho., 17 (1990) 1551–1554.

    PubMed  CAS  Google Scholar 

  32. Fujimoto S, Takahashi M, Metou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery, Cancer, 79 (1997) 884–891.

    Article  PubMed  CAS  Google Scholar 

  33. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, and Hiraoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients, J. Cancer Res. Clin. Oncol., 108 (1984) 236–238.

    Article  PubMed  CAS  Google Scholar 

  34. Fujimoto S, Takahashi M, Kobayashi K, Kasanuki J, and Ohkubo H. Heated intraperitoneal mitomycin C infusion treatment for patients with gastric cancer and peritoneal metastasis, Cancer Treat. Res., 81 (1996) 239–245.

    Article  PubMed  CAS  Google Scholar 

  35. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, and Yamaguchi T. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles, World J. Surg., 19 (1995) 565–569.

    Article  PubMed  CAS  Google Scholar 

  36. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer, Semin. Oncol., 23 (1996) 379–389.

    PubMed  CAS  Google Scholar 

  37. Ajani JA, Mansfield PF, and Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy, World J. Surg., 19 (1995) 216–220.

    Article  PubMed  CAS  Google Scholar 

  38. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil, J. Clin. Oncol., 14 (1996) 1818–1828.

    PubMed  CAS  Google Scholar 

  39. Leichman L, Silberman H, Leichman CG, et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program, J. Clin. Oncol., 10 (1992) 1933–1942.

    PubMed  CAS  Google Scholar 

  40. Crookes P, Leichman CG, Leichman L, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report, Cancer, 79 (1997) 1767–1775.

    Article  PubMed  CAS  Google Scholar 

  41. Ajani JA, Mansfield PF, Janjan N, et al. Preoperative chemoradiation therapy in patients with potentially resectable gastric carcinoma: a multi-institutional pilot, Proc. Am. Soc. Clin. Oncol., 16 (1998) 1089.

    Google Scholar 

  42. Fata F, Baylor L, Karpeh M, et al. Thymidylate synthetase (TS) is not an independent predictor of outcome in patients with operable gastric cancer, Proc. Am. Soc. Clin. Oncol., 16 (1998) 1079.

    Google Scholar 

  43. Danenberg K, Salonga D, Park JM, et al. Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthetase (TS) gene expressions identify a high percentage of colorectal tumors responding to 5fluorouracil (5-FU), Proc. Am. Soc. Clin. Oncol., 16 (1998) 992.

    Google Scholar 

  44. Saltz L, Danenberg K, Paty P, et al. High thymidylate synthetase (TS) expression does not preclude activity of CPT-11 in colorectal cancer, Proc. Am. Soc. Clin. Oncol., (1998) 1080.

    Google Scholar 

  45. Metzger R, Leichman CG, Danenberg K, et al. ERCC 1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy, J. Clin. Oncol., 16 (1998) 309–316.

    PubMed  CAS  Google Scholar 

  46. Watanabe A. Evaluation of therapeutic effect on lung cancer and mediastinal tumor by 18f-fluoro-2deoxy-d-gluocose (FDG) positron emission tomography, Proc. Am. Soc. Clin. Oncol., 16 (1998) 1943.

    Google Scholar 

  47. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients, Lancet, 345 (1995) 745–748.

    Article  PubMed  CAS  Google Scholar 

  48. Smith JW, Shiu MH, Kelsey L, and Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma, Arch. Surg., 126 (1991) 1469–1473.

    Article  PubMed  CAS  Google Scholar 

  49. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group, Gan To Kagaku Ryoho., 21 (1994) 1033–1038.

    PubMed  CAS  Google Scholar 

  50. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer, J. Clin. Oncol., 15 (1997) 921–927.

    PubMed  CAS  Google Scholar 

  51. Ajani JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas, Semin. Oncol., 23 (Suppl. 12) (1996) 55–58.

    PubMed  CAS  Google Scholar 

  52. Ilson DH and Kelsen DP. Adjuvant postoperative therapy of gastrointestinal malignancies, Oncology, 8 (1994) 75–83,88–90,95.

    PubMed  CAS  Google Scholar 

  53. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group, Br. J. Cancer 70 (1994) 380–383.

    Article  PubMed  CAS  Google Scholar 

  54. Kaye SB. Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer, Semin. Oncol., 22 (Suppl 4) (1995) 30–33.

    PubMed  CAS  Google Scholar 

  55. Christman K, Kelsen D, Saltz L, and Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer, Cancer, 73 (1994) 5–7.

    Article  PubMed  CAS  Google Scholar 

  56. Sessa C, Aamdal S, Wolff I, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group, Ann. Oncol., 5 (1994) 471–472.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Eileen M. O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Kelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

O’Reilly, E.M., Kelsen, D.P. (2000). Memorial Sloan-Kettering Cancer Center Experience with Intraperitoneal Chemotherapy for Gastric Cancer. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_15

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation